An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection.

Miao, Xiaolong; Wu, Zelai; Jiang, Yuancong; Liu, Han; Gong, Weihua

Miao, Xiaolong; Wu, Zelai; Jiang, Yuancong; Liu, Han; Gong, Weihua.

Afiliación

Miao X; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Wu Z; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Jiang Y; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Liu H; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Gong W; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.

Immunology ; 169(2): 157-166, 2023 06.

Article en En | MEDLINE | ID: mdl-36517459

Asunto(s)

Antineoplásicos; Neoplasias Hepáticas; Humanos; Animales; Ratones; Antígeno B7-H1/metabolismo; Interferón gamma; Inmunoterapia/métodos; Aloinjertos/metabolismo

Palabras clave

BET protein inhibition; PD-L1; allograft rejection; immunotherapy; primary liver cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Immunology Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google